The synthetic
peptide CKS-17 has homology to a highly conserved region of the immunosuppressive retroviral envelope
protein P15E, to envelope
proteins of HTLV I, II, III, and to that encoded by an endogeneous C-type human retroviral
DNA.
CKS-17 inhibits the immune response of lymphocytes and the respiratory burst of human monocytes. Because P15E-related
antigens are present in human malignant cell lines and cancerous effusions, we sought to determine the effect of
CKS-17 on monocyte-mediated
tumor cell lysis. Lysis of A375
tumor cells by lymphokine or
lipopolysaccharide-activated human monocytes was inhibited by 10 microM
CKS-17 (control, 79%;
CKS-17-treated, 19%). Another synthesized
peptide, CS-2, which has partial homology to
CKS-17, failed to block monocyte-mediated killing. Thus, the inhibition by
CKS-17 appeared to be specific. Because
interleukin 1 (IL-1) is a cytocidal factor produced by activated monocytes, we also investigated the effect of
CKS-17 on
IL-1 production by monocytes and on direct IL-1-mediated cytotoxicity.
CKS-17 did not block production or secretion of
IL-1 by
lipopolysaccharide- or
interferon-gamma-activated monocytes. However, the direct cytocidal activity of both recombinant
IL-1 alpha and
IL-1 beta against A375
tumor cells was blocked by
CKS-17. The cytotoxic activity of
IL-1 was inhibited by
CKS-17 if (a)
IL-1 was preincubated with
CKS-17 for 1 hr at 37 degrees C or (b) the A375 cells were incubated with
CKS-17 for 1 hr prior to the addition of
IL-1.
CKS-17 also blocked IL-1-induced proliferation of murine thymocytes, the D10 T cell line, and an IL-1-responsive
astrocytoma cell line. These data suggest that
CKS-17 may be a potent inhibitor of
IL-1.